484 related articles for article (PubMed ID: 19920160)
1. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
8. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
10. Tolterodine for the treatment of overactive bladder.
Salvatore S; Serati M; Bolis P
Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
13. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
[TBL] [Abstract][Full Text] [Related]
15. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
[TBL] [Abstract][Full Text] [Related]
17. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
18. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
19. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
20. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
[Next] [New Search]
